{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:15:53Z","timestamp":1777518953281,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,6,1]],"date-time":"2002-06-01T00:00:00Z","timestamp":1022889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2002,6]]},"DOI":"10.1016\/s0169-409x(02)00020-0","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T03:08:04Z","timestamp":1034305684000},"page":"453-456","source":"Crossref","is-referenced-by-count":97,"title":["Introduction and overview of peptide and protein pegylation"],"prefix":"10.1016","volume":"54","member":"78","reference":[{"key":"10.1016\/S0169-409X(02)00020-0_BIB1","series-title":"Poly(Ethylene Glycol) Chemistry, Biotechnical and Biomedical Applications","year":"1992"},{"key":"10.1016\/S0169-409X(02)00020-0_BIB2","series-title":"Poly(Ethylene Glycol) Chemistry and Biological Applications","year":"1997"},{"key":"10.1016\/S0169-409X(02)00020-0_BIB3","series-title":"Peptide and Protein Drug Delivery","article-title":"Reduction of immunogenicity and extension of circulating half-life of peptide and protein","author":"Davis","year":"1990"},{"key":"10.1016\/S0169-409X(02)00020-0_BIB4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0169-409X(91)90037-D","article-title":"The therapeutic value of poly(ethylene glycol) modified protein","volume":"6","author":"Nucci","year":"1991","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/S0169-409X(02)00020-0_BIB5","first-page":"249","article-title":"The uses and properties of PEG-linked proteins","volume":"9","author":"Delgado","year":"1992","journal-title":"Crit. Rev. Ther. Drug Carrier Systems"},{"key":"10.1016\/S0169-409X(02)00020-0_BIB6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0169-409X(93)90005-O","article-title":"The conjugation of proteins with poly(ethylene glycol)and other polymers. Altering properties of proteins to enhance their therapeutic potential","volume":"10","author":"Katre","year":"1993","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/S0169-409X(02)00020-0_BIB7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0167-7799(00)88912-X","article-title":"Biomedical and biotechnological application of PEG and PEG-modified proteins","volume":"13","author":"Inada","year":"1995","journal-title":"Tibtech"},{"key":"10.1016\/S0169-409X(02)00020-0_BIB8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1021\/bc970184f","article-title":"Stabilization of substances in the circulation","volume":"9","author":"Monfardini","year":"1998","journal-title":"Bioconj. Chem."},{"key":"10.1016\/S0169-409X(02)00020-0_BIB9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1461-5347(98)00086-8","article-title":"Polyethylene glycol-conjugated pharmaceutical proteins","author":"Bailon","year":"1998","journal-title":"Pharm. Sci. Technol. Today (PSTT)"},{"key":"10.1016\/S0169-409X(02)00020-0_BIB10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0142-9612(00)00193-9","article-title":"Peptide and protein PEGylation: a review of problems and solutions","volume":"22","author":"Veronese","year":"2001","journal-title":"Biomaterials"},{"key":"10.1016\/S0169-409X(02)00020-0_BIB11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0006-2952(87)90387-X","article-title":"Covalent linkage of carboxypeptidase to soluble dextran. Properties of conjugates and effects on plasma persistence in mice","volume":"36","author":"Melton","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/S0169-409X(02)00020-0_BIB12","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02025941","article-title":"Enhanced anti-inflammatory effects and reduced immunogenicity of bovine liver superoxide dismutase by conjugation with homologous albumin","volume":"10","author":"Wong","year":"1980","journal-title":"Agent Action"},{"key":"10.1016\/S0169-409X(02)00020-0_BIB13","first-page":"21","article-title":"The use of immobilised streptokinase (Strptodekaza) for the therapy of thromboses","volume":"54","author":"Torchilin","year":"1982","journal-title":"Ther. Arch."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X02000200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X02000200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T15:56:33Z","timestamp":1555170993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X02000200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,6]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["S0169409X02000200"],"URL":"https:\/\/doi.org\/10.1016\/s0169-409x(02)00020-0","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2002,6]]}}}